BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...
BioCentury | May 21, 2020

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still...
BioCentury | May 20, 2020

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective targeted protein degraders by using its covalent chemistry to engage untapped ubiquitin ligases. Targeted protein degraders typically connect one...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...
BioCentury | Apr 10, 2020
Product Development

April 9 Quick Takes: BMS tops off CAR T patent win; plus approval for Braftovi plus Erbitux, Merck, BMS, Liquidia, Circassia-AZ, Bridge

Award swells to $1.2B, plus royalties, in Kite CAR T suit  Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a...
BioCentury | Mar 13, 2020

Nurix raises $120M in week’s second major protein degradation financing

Nurix’s $120 million funding round is the second fund-raising for a targeted protein degradation company in excess of $100 million this week. Along with Kymera’s $102 million round, Nurix’s deal reflects the promise investors see...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...
BioCentury | Feb 8, 2020
Tools & Techniques

Beyond PROTACs and the proteasome: broadening the TAC toolbox

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...
BioCentury | Jan 31, 2020
Distillery Therapeutics

Promoting RNF208 expression in metastatic breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Increasing the expression of RNF208, an estrogen-inducible E3 ligase, could treat metastatic triple-negative breast cancer (TNBC). RNA levels of RNF208 were lower in tumor tissue from patients with TNBC...
BioCentury | Dec 19, 2019

Boehringer deal, clinical milestones support Bridge IPO

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...
Items per page:
1 - 10 of 202